Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
P/S ratio for Idorsia Ltd (IDIA.SW)
P/S ratio as of 2023: 2.47
According to Idorsia Ltd's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.47. At the end of 2022 the company had a P/S ratio of 24.52.
P/S ratio history for Idorsia Ltd from 2016 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 2.47 |
| 2022 | 24.52 |
| 2021 | 88.85 |
| 2020 | 50.79 |
| 2019 | 167.11 |
| 2018 | 35.73 |
| 2017 | 18.60 |
| 2016 | 0.00 |